Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Compare

317 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZNTL Analyst Ratings

Moderate Buy

5 Buy

4 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Zentalis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZNTL Stock 12 Month Forecast

Average Price Target

$7.13

▲(378.52%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Zentalis Pharmaceuticals in the last 3 months. The average price target is $7.13 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 378.52% change from the last price of $1.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.9507692307692308,2.621538461538462,3.292307692307692,3.9630769230769234,4.633846153846154,5.304615384615385,5.975384615384615,6.6461538461538465,7.316923076923078,7.987692307692308,8.658461538461538,9.329230769230769,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.73,2.1799999999999997,2.63,3.08,3.5300000000000002,3.9799999999999995,4.43,4.88,5.33,5.78,6.2299999999999995,6.68,{"y":7.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.4892307692307694,1.6984615384615385,1.9076923076923076,2.1169230769230767,2.3261538461538462,2.5353846153846153,2.7446153846153845,2.953846153846154,3.1630769230769227,3.3723076923076922,3.581538461538462,3.7907692307692304,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.41,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$7.13

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$10

Buy

571.14%

Upside

Reiterated

06/02/25

Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals' Azenosertib

Andrew BerensLeerink Partners

Leerink Partners

Hold

235.57%

Upside

Reiterated

05/16/25

Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management

Derek ArchilaWells Fargo

Wells Fargo

Hold

302.68%

Upside

Reiterated

05/15/25

Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline

Robert DriscollWedbush

Wedbush

Hold

168.46%

Upside

Reiterated

05/15/25

Matthew BieglerOppenheimer

Oppenheimer

$10→$9

Buy

504.03%

Upside

Reiterated

05/15/25

Zentalis price target lowered to $9 from $10 at OppenheimerZentalis price target lowered to $9 from $10 at Oppenheimer

Michael SchmidtGuggenheim

Guggenheim

Buy

302.68%

Upside

Reiterated

05/14/25

Guggenheim Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Initiated

05/14/25

Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

Buy

504.03%

Upside

Reiterated

03/27/25

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

Michael UlzMorgan Stanley

Morgan Stanley

Hold

436.91%

Upside

Reiterated

03/27/25

Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty

Akash TewariJefferies

Jefferies

$6→$2.5

Hold

67.79%

Upside

Reiterated

01/29/25

Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.50 at JefferiesJefferies analyst Akash Tewari lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.50 (from $6.00) while maintaining a Hold rating.

Eliana MerleUBS

UBS

$5→$2.2

Hold

47.65%

Upside

Reiterated

01/28/25

Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.20 at UBSUBS analyst Eliana Merle lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.20 (from $5.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$10

Buy

571.14%

Upside

Reiterated

06/02/25

Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals' Azenosertib

Andrew BerensLeerink Partners

Leerink Partners

Hold

235.57%

Upside

Reiterated

05/16/25

Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management

Derek ArchilaWells Fargo

Wells Fargo

Hold

302.68%

Upside

Reiterated

05/15/25

Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline

Robert DriscollWedbush

Wedbush

Hold

168.46%

Upside

Reiterated

05/15/25

Matthew BieglerOppenheimer

Oppenheimer

$10→$9

Buy

504.03%

Upside

Reiterated

05/15/25

Zentalis price target lowered to $9 from $10 at OppenheimerZentalis price target lowered to $9 from $10 at Oppenheimer

Michael SchmidtGuggenheim

Guggenheim

Buy

302.68%

Upside

Reiterated

05/14/25

Guggenheim Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Initiated

05/14/25

Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

Buy

504.03%

Upside

Reiterated

03/27/25

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

Michael UlzMorgan Stanley

Morgan Stanley

Hold

436.91%

Upside

Reiterated

03/27/25

Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty

Akash TewariJefferies

Jefferies

$6→$2.5

Hold

67.79%

Upside

Reiterated

01/29/25

Eliana MerleUBS

UBS

$5→$2.2

Hold

47.65%

Upside

Reiterated

01/28/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zentalis Pharmaceuticals

1 Month

xxx

Success Rate

5/16 ratings generated profit

Average Return

-13.08%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 31.25% of your transactions generating a profit, with an average return of -13.08% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

-7.99%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -7.99% per trade.

1 Year

Matthew BieglerOppenheimer

Success Rate

1/17 ratings generated profit

Average Return

-47.49%

reiterated a buy rating 27 days ago

Copying Matthew Biegler's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -47.49% per trade.

2 Years

xxx

Success Rate

1/17 ratings generated profit

Average Return

-63.44%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -63.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZNTL Analyst Recommendation Trends

Rating

Nov 24

Jan 25

Mar 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZNTL has received 12 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ZNTL average Analyst price target in the past 3 months is 7.13.

Each month's total comprises the sum of three months' worth of ratings.

ZNTL Financial Forecast

ZNTL Earnings Forecast

Next quarter’s earnings estimate for ZNTL is -$0.54 with a range of -$0.81 to -$0.43. The previous quarter’s EPS was -$0.67. ZNTL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.

ZNTL Sales Forecast

Next quarter’s sales forecast for ZNTL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ZNTL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.

ZNTL Stock Forecast FAQ

What is ZNTL’s average 12-month price target, according to analysts?

Based on analyst ratings, Zentalis Pharmaceuticals’s 12-month average price target is 7.13.

What is ZNTL’s upside potential, based on the analysts’ average price target?

Zentalis Pharmaceuticals has 378.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZNTL a Buy, Sell or Hold?

Zentalis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.

What is Zentalis Pharmaceuticals’s price target?

The average price target for Zentalis Pharmaceuticals is 7.13. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 378.52% Increase from the current price of $1.49.

What do analysts say about Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ZNTL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

ZNTL Analyst Ratings

ZNTL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zentalis Pharmaceuticals

ZNTL Analyst Recommendation Trends

ZNTL Financial Forecast

ZNTL Earnings Forecast

ZNTL Sales Forecast

ZNTL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts